Loading
journalsJournal
Cancer research communications
Cancer Research Communications is the AACR's fully open-access journal for rapid publication across all of cancer research, including confirmatory and null results. Read by researchers who want AACR peer review without a paywall.
Also called: Cancer Res CommunCancer Research Communications
Overview
Cancer Research Communications is an open access, peer-reviewed journal of the American Association for Cancer Research launched in October 2021 and published monthly since 2022. It covers the full spectrum of cancer research, aiming to accelerate discovery by rapidly publishing hypotheses, methods, results, data resources and new knowledge; articles may report novel findings, support previously published results or present thought-provoking null results. Its sections span molecular and cellular biology, tumour biology, immuno-oncology, emerging technologies and data science, therapeutic development, precision medicine and biomarkers, clinical research and trials, epidemiology and prevention, and health disparities. All content is free to read under the Budapest Open Access Initiative definition; DOAJ records the CC BY licence, an article processing charge with discounts, anonymous peer review and author retention of copyright. Indexed in MEDLINE and deposited in PubMed Central.
Publisher
American Association for Cancer Research · American Association for Cancer Research
Scope
cancer research
Access model
open access
Founded
2021
ISSN
2767-9764
observational20257 citations
First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
This is the paper Europe PMC returns for registry id NCT05199272 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observational20253 citations
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
One of the most cited trial reports Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
observationalCancer research communications 20257 citations
First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
This is the paper Europe PMC returns for registry id NCT05199272 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observationalCancer research communications 20253 citations
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
One of the most cited trial reports Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Similar pages
- JournalBlood cancer discovery
Shares American Association for Cancer Research (AACR), PubMed & Europe PMC.
- JournalCancer prevention research
Shares American Association for Cancer Research (AACR), PubMed & Europe PMC.
- JournalMolecular cancer research
Shares American Association for Cancer Research (AACR), PubMed & Europe PMC.
institutions
collections
key papers
First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid MalignanciesPhase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer